Geoffrey Smith, MD, PhD
Attending, Cancer and Blood Disorders Center
Image
Geoffrey Smith, MD, PhD
Attending, Cancer and Blood Disorders Center
Medical Services
Languages
English
Education
Undergraduate School
Harvard College
2010
Cambridge
MA
Graduate School
University of California, San Francisco
2017
San Francisco
CA
Medical School
University of California, San Francisco
2019
San Francisco
CA
Residency
Pediatrics
Boston Combined Residency Program (BCRP)
2021
Boston
MA
Fellowship
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2025
Boston
MA
Certifications
American Board of Pediatrics (General)
Professional History
Dr. Smith earned his A.B. in Chemistry at Harvard College and pursued his MD and PhD at the University of California, San Francisco. He returned to Boston for Pediatrics Residency at Boston Children’s Hospital and Boston Medical center followed by Pediatric Hematology / Oncology fellowship in the Boston Children’s / Dana-Farber Cancer and Blood Disorder center. He is currently an instructor and attends on the inpatient oncology services. His research focuses on the development of novel immunotherapies for pediatric solid tumors, with a special emphasis on osteosarcoma.
Publications
A Resident-Led Virtual Journal Club to Educate Pediatric Residents About Coronavirus Disease 2019. View Abstract
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. View Abstract
IL-2Rß abundance differentially tunes IL-2 signaling dynamics in CD4+ and CD8+ T cells. View Abstract
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. View Abstract
IL-2 Modulates the TCR Signaling Threshold for CD8 but Not CD4 T Cell Proliferation on a Single-Cell Level. View Abstract
Regulation of B cell fate by chronic activity of the IgE B cell receptor. View Abstract
Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. View Abstract
Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex. View Abstract